Treatment options along with opportunities to tailor therapy for patients with breast cancer are evolving rapidly. Guidelines were published in 2017 and 2018 offer new insights into the optimal treatment of patients with breast cancer. Emerging evidence suggests that combination therapy with RT and check punt inhibitors, as well as gene expression profiling, specifically the identification of intrinsic molecular subclassifications, and/or the use of novel biomarkers combined with traditional prognostic factors, may enhance treatment and improve outcomes. The ASCO guidelines were updated in 2017 and 2018 to incorporate some of these new developments.In addition, several new medications have been approved within the last year and data on other emerging therapeutics has recently been published.
The goal of this conference is to educate the medical and global community in a forum that will foster communication to benefit the individual patient as well as the community.